Full results & analysis
Available in the Gosset platform where reported.
01
Overview
Phase 2, open-label, single-arm trial of imatinib in gastrointestinal stromal tumor (GIST), sponsored by Novartis. Primary endpoint: Antineoplastic effect. Started Sep 2002; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Imatinib Mesylate
400 mg once daily
03
Who it enrols
Patients with malignant GIST who completed the CSTI571B1201 study.
04
Endpoints
Primary
Antineoplastic effect
Secondary
Safety
Pharmacokinetics
Beyond the preview
Go deeper on NCT00237172.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00237172.